Oxford trial chief says its Covid vaccine could still be ready at a similar time to others  CNBCView Full coverage on Google News

LONDON (Reuters) - AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.LONDON (Reuters) - AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.

AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas | The Star

Brazil's sudden suspension of Chinese COVID-19 vaccine trials on November 9 raised concerns about obstacles China faces in exporting its vaccines. Although clinical trials of the vaccine soon resumed in Brazil, political wrangling behind multi-layered stakeholders and commercial interests in host countries pose increasing potential risks to Chinese vaccines' distribution abroad.

What potential risks lay ahead for China’s COVID-19 vaccine export? - Global Times

As we edge ever closer to a Covid vaccine, the arguments for making it mandatory grow ever louder. This is wrong. I will be first in the queue to get it, but forcing people to do so breaches their human rights.As we edge ever closer to a Covid vaccine, the arguments for making it mandatory grow ever louder. This is wrong. I will be first in the queue to get it, but forcing people to do so breaches their human rights.

I understand why some people are nervous about a Covid vaccine, but open debate is the answer… NOT making immunisation compulsory — RT Op-ed

Dr. Anthony Fauci: When the COVID-19 vaccine gets approved by the FDA, I would take the vaccine and I would recommend that my family take the vaccine.Dr. Anthony Fauci: When the COVID-19 vaccine gets approved by the FDA, I would take the vaccine and I would recommend that my family take the vaccine.

In coronavirus war, help is on the way with vaccine: Anthony Fauci Q&A

A week after one of its tests in Brazil was stopped amid a safety scare, Chinese biotech Sinovac has published data showing its experimental COVID-19 vaccine can quickly boost an immune response.A week after one of its tests in Brazil was stopped amid a safety scare, Chinese biotech Sinovac has published data showing its experimental COVID-19 vaccine can quickly boost an immune response.

China's Sinovac sees speedy immune response with COVID-19 shot in early trials | FierceBiotech

Spain's medicines agency authorised the launch of late-stage trials of Johnson & Johnson's COVID-19 vaccine on Wednesday as the race to develop successful vaccines intensifies. The Phase III trial of the two-dose vaccination will be carried out in nine hospitals throughout Spain on volunteers both with and without previous health conditions, the AEMPS agency said in a statement. J&J started mid-stage phase II trials in Spain and other countries in September and launched a late-stage trial in Britain on Monday.Spain's medicines agency authorised the launch of late-stage trials of Johnson & Johnson's COVID-19 vaccine on Wednesday as the race to develop successful vaccines intensifies. The Phase III trial of the two-dose vaccination will be carried out in nine hospitals throughout Spain on volunteers both with and without previous health conditions, the AEMPS agency said in a statement. J&J started mid-stage phase II trials in Spain and other countries in September and launched a late-stage trial in Britain on Monday.

Spain authorises Phase III trial of Johnson & Johnson COVID-19 vaccine

Five Chinese vaccines undergo phase-III clinical trials overseas - CGTN

Turkey is holding talks for the procurement of a potential vaccine developed by Pfizer and its German partner BioNTech, the country’s health minister has said.Turkey is holding talks for the procurement of a potential vaccine developed by Pfizer and its German partner BioNTech, the country’s health minister has said.

Turkey in talks for Pfizer’s COVID-19 vaccine - Turkey News

Hundreds of thousands of people in China have already received this vaccine. Now, preliminary trials are showing promising results, although it's too early to say whether it can prevent disease.Hundreds of thousands of people in China have already received this vaccine. Now, preliminary trials are showing promising results, although it's too early to say whether it can prevent disease.

Early Trials Of Sinovac's Vaccine Show It Triggers An Immune Response : Coronavirus Updates : NPR

Daijiworld - A News portal linking West coast of India and the World

The phase two trial results raise hopes the jab can protect age groups most at risk from Covid-19.The phase two trial results raise hopes the jab can protect age groups most at risk from Covid-19.

sign-in

Pakistan News: The funds were approved for the initial purchase with the decision that vulnerable segments like senior citizens, health practitioners and those havinPakistan News: The funds were approved for the initial purchase with the decision that vulnerable segments like senior citizens, health practitioners and those havin

Pakistan allocates $100 million for advance procurement of Covid-19 vaccine - Times of India

YouTube is adding information progress towards a COVID-19 vaccine to information panels under relevant videos and searches. It’s a small attempt by the Google-owned company to preemptively combat misinformation about future vaccines for the novel coronavirus.That oughta do it

YouTube is adding information about COVID-19 vaccines to its fact-check panels - The Verge

Very encouraging results from the Oxford Vaccine trialNovember turned out to be the month of good Covid-19 vaccine news. After the promising interim results of the Pfizer and Moderna Phase 3 trials, the result

Oxford Vaccine Safe And Effective In Older Adults As Well, Phase 2 Data Shows | IFLScience

Sinovac Biotech is conducting phase three trials in Indonesia, Brazil and Turkey. Unlike Pfizer-BioNtech and Moderna vaccines, its vaccine can be stored at a temperature between 2 and 8 degrees Celsius in any refrigerator at home and is stable for up to three years. A government campaign is trying to overcome the effect of past vaccine scandals.   Sinovac Biotech is conducting phase three trials in Indonesia, Brazil and Turkey. Unlike Pfizer-BioNtech and Moderna vaccines, its vaccine can be stored at a temperature between 2 and 8 degrees Celsius in any refrigerator at home and is stable for up to three years. A government campaign is trying to overcome the effect of past vaccine scandals.  

CHINA Chinese experimental vaccine induces a quick response

Women slightly less likely than men to be vaccinated, and those 55 and older less likely to hesitateWomen slightly less likely than men to be vaccinated, and those 55 and older less likely to hesitate

Disadvantaged and strongly religious people less likely to get Covid vaccine – survey | Health | The Guardian

LONDON: University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas, a key researcher said Thursday as he discussed the team’s latest findings. Dr. Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase III trials areLONDON: University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas, a key researcher said Thursday as he discussed the team’s latest

Oxford scientists expect COVID-19 vaccine data by Christmas | Arab News

Two weeks after volunteers were administered a second dose, over 99 percent of them had neutralising antibody responses regardless of age.Two weeks after volunteers were administered a second dose, over 99 percent of them had neutralising antibody responses regardless of age.

Oxford vaccine candidate found safe in elderly, offered immunity against SARS-CoV-2 in all age groups- Technology News, Firstpost

Results of late-stage trials of University of Oxford's Covid-19 vaccine candidate should definitely be known by Christmas, the chief investigator on the study said on Thursday, adding it was too early to know its efficacy yet.Results of late-stage trials of University of Oxford's Covid-19 vaccine candidate should definitely be known by Christmas, the chief investigator on the study said on Thursday, adding it was too early to know its efficacy yet.

Oxford's Covid-19 vaccine trial results 'definitely' before Christmas, says investigator | News | ekathimerini.com

Turkey in talks with Pfizer for 25 million doses of coronavirus vaccine: Health Minister KocaTurkey is in talks with Pfizer for a million doses of the coronavirus vaccine by year-end and 25 million more in 2021, Health Minister Fahrettin Koca said in a statement late...

Turkey in talks with Pfizer for 25 million doses of coronavirus vaccine: Health Minister Koca | Daily Sabah

Yuli Edelstein asks judges for legal advice on ensuring national inoculation, including taking into account fear that rapid development could have led to an unsafe productYuli Edelstein asks judges for legal advice on ensuring national inoculation, including taking into account fear that rapid development could have led to an unsafe product

Health Minister said to mull law making coronavirus vaccination compulsory | The Times of Israel

Results from an early-phase randomised clinical trial of the Chinese Covid-19 vaccine candidate CoronaVac show that the formulation appears safe and induces an antibody response in...Results from an early-phase randomised clinical trial of the Chinese Covid-19 vaccine candidate CoronaVac show that the formulation appears safe and induces an antibody response in...

China’s Covid vaccine appears safe, causes immune response - world news - Hindustan Times

Bloomberg - Are you a robot?

Official site of The Week Magazine, offering commentary and analysis of the day's breaking news and current events as well as arts, entertainment, people and gossip, and political cartoons. Early-stage trials indicated that British drug maker AstraZeneca's coronavirus vaccine, which it is developing with the University of Oxford, was safe and effective, according to results published Thursday in The Lancet, a top medical journal. The study of 560 healthy adults found that the vaccine produced a similar immune response in all adults, meaning it could protect older people who face a "significant risk" of developing a severe illness if they are infected with the coronavirus. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society," said Dr. Maheshi Ramasamy, a co-author of the study at the University of Oxford, "but further research will be needed before we can be sure." Harold Maass

AstraZeneca's coronavirus vaccine triggers immune response in older people

Mistrust of the medical establishment, based on experience, is behind hesitancy.Mistrust of the medical establishment, based on experience, is behind hesitancy.

Black people have a long history of poor medical treatment – no wonder many are hesitant to take COVID vaccines

Black people have a long history of poor medical treatment – no wonder many are hesitant to take COVID vaccines

Researchers around the world are trying to develop safe and effective vaccines against SARS-CoV-2, the virus that causes COVID-19. Here's their progress so far.Researchers around the world are trying to develop safe and effective vaccines against SARS-CoV-2, the virus that causes COVID-19. Here's their progress so far.

When will we have a COVID-19 vaccine? | Science| In-depth reporting on science and technology | DW | 18.11.2020

Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.

Oxford vaccine is safe and provokes response in adults over 56, study finds | Euronews

Early-phase trials for China's latest vaccine have proven "safe" and produced antibody responses in volunteers aged 18 to 59 years, a major study revealed on Tuesday.Early-phase trials for China's latest vaccine have proven "safe" and produced antibody responses in volunteers aged 18 to 59 years, a major study revealed on Tuesday.

China's CoronaVac Triggers Rapid Immune Response In Preliminary Volunteer Trials, Lancet Study Finds - Sputnik International

Pakistan received approval from its main regulator on health, the National Institute of Health, to begin a Phase 3 study using the CanSino vaccine developed in China by CanSino Biologics.If the...Pakistan received approval from its main regulator on health, the National Institute of Health, to begin a Phase 3 study using the CanSino vaccine developed in China by CanSino Biologics.If the...

Incompetence, conspiracy and citizenship

In The News is a roundup of stories from The Canadian Press designed to kickstart your day. Here is what's on the radar of our editors for the morning of Nov. 19 ... What we are watching in Canada ...In The News is a roundup of stories from The Canadian Press designed to kickstart your day. Here is what's on the radar of our editors for the morning of Nov. 19 ... What we are watching in Canada ...

Vaccines coming to Canada and tighter restrictions: In The News for Nov. 19 - Sudbury.com

The experimental COVID-19 vaccine being developed by AstraZeneca and Oxford University produces a strong immune response in older adults, data from early...The experimental COVID-19 vaccine being developed by AstraZeneca and Oxford University produces a strong immune response in older adults, data from early...

AstraZeneca's COVID-19 vaccine shows 'encouraging' immune response in older adults - MarketWatch

Nearly one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country's emergency use programme, the firm said late on Wednesday.Nearly one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country's emergency use programme, the firm said late on Wednesday.

China Sinopharm's coronavirus vaccine taken by about a million people in emergency use | Reuters

AstraZeneca and Oxford University's potential Covid-19 vaccine produced a strong immune response in older adults, data published yesterday showed as the world Health Organisation warned that vaccines would not arrive in time to defeat the second wave of the pandemic.  The data, reported in part last month but published in full in The Lancet medical journal yesterday, suggestAstraZeneca and Oxford University’s potential Covid-19 vaccine produced a strong immune response in older adults, data published yesterday showed as the world Health Organisation warned that vaccines

Oxford Covid vaccine safe for older adults | The Daily Star

Older adults are at higher risk of infection and death from covid-19, and are a priority for immunization whenever a final vaccine emerges from the ongoing trialsOlder adults are at higher risk of infection and death from covid-19, and are a priority for immunization whenever a final vaccine emerges from the ongoing trials

Oxford jab triggers robust immune response in elderly

LONDON: Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing ...LONDON: Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing ...

Oxford COVID-19 trial will look at interim Phase III data after 53 infections: Investigator - CNA

The Covid-19 vaccine being developed by AstraZeneca and Oxford University is showing promising results among the older population, new data published in The Lancet shows.The Covid-19 vaccine being developed by AstraZeneca and Oxford University is showing promising results among the older population, new data published in The Lancet shows.

AstraZeneca's vaccine effective among older people, results show